Arkolith/Insider Trading/FBRX/Form 4

Wagner Paul A.

SEE REMARKS, DirectorForte Biosciences, Inc. (FBRX) · full profile →Form 4 · filed Jan 2, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 1, 2026Option exercise(M)1K—$083K
Jan 1, 2026Tax withholding(F)164$27.27$4K83K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 1, 2026Option exercise(M)1K—$05K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001612842-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML